Warburg Pincus in Talks to Acquire Maneesh Pharma's Doxinate Portfolio in Rs 1,800 Cr Deal: Report
Mumbai: The US-based private equity firm Warburg Pincus is in advanced discussions to acquire the formulations business of Maneesh Pharmaceuticals in a deal estimated to be valued at around Rs 1,600-Rs 1,800 crore.
According to a recent media report in The Economic Times, sources indicate that both parties have entered into an exclusivity agreement, and negotiations are currently in the final stages.
The proposed acquisition is expected to focus on the company’s non-tuberculosis (non-TB) portfolio, which has drawn significant investor interest due to its broader commercial viability. Maneesh Pharmaceuticals, a Mumbai-based company founded in 1985, has established its presence across multiple therapeutic segments including gynaecology, antibiotics, gastrointestinal disorders, and pain management.
The company is known for several established brands, notably Doxinate, widely used in the management of nausea and vomiting during pregnancy, and Smyle Mouth Ulcer Gel. Over the years, it has built a strong domestic footprint supported by a diversified product portfolio.
Industry sources suggest that the promoters have been exploring strategic stake sale options for some time. However, the company’s anti-TB segment had earlier posed challenges in attracting investors, leading to a more focused interest in carving out the non-TB business.
Financially, the company has demonstrated stable performance, reporting an annual turnover of approximately ₹500 crore, with key brands contributing significantly to revenue generation. Doxinate alone is estimated to account for a substantial share of the company’s annual sales.
The Economic Times (Pharma) reports that the deal is likely to be concluded and formally announced within the next three to four months, subject to final agreements and regulatory considerations.
